Biogenerix Pages on BioPortfolio:

BioPortfolio Bulletin - Jobs, Reports, Business Contacts, Conferences
Development of biogeneric molecules for sale in the potentially highly lucrative US and Western European markets depends on the ability to answer three key ...
http://www.bioportfolio.co.uk/bulletin_62.htm...

BioPortfolio Bulletin - Targeted Email Delivery, BIOPHARMA Reports
Now includes European/EU products;; Indexes — 24000+ index entries; Includes all US, and European products, and many biodefense and biogeneric products ...
http://www.bioportfolio.co.uk/bulletin_67.htm...

Biogenerics, World Market
1 Apr 2008 ... Worldwide interest in biogenerics or biosimilars is gaining momentum. Since Kalorama Information last visited the market for synthetic or ...
http://www.bioportfolio.com/cgi-bin/acatalog/Biogenerics__Wo...

Omnitrope deferral casts doubt over biogeneric development
Approval of the first biogeneric in both Europe and the US is expected to pave the way for ... Biogenerics: Drivers and Resistors of Market Development ...
http://www.bioportfolio.com/news/datamonitor_87.htm...

Patent expiry of epoetin alfa in Europe attracts 10 companies with ...
6 Oct 2005 ... Among the 10 companies with biogeneric EPO projects are subsidiaries or ... Major players of first generation EPO biogenerics are Dragon ...
http://www.bioportfolio.com/biotech_news/lamerie_2.htm...

Global BioGenerics Market in 2010
BioGenerics is an umbrella term used to define the market for bioequivalent products based on the same biological substance used in off-patent biologics.
...
http://www.bioportfolio.com/cgi-bin/acatalog/Global_BioGener...

BioPortfolio Bulletin - CNS Disorders Alzheimer's Disease Multiple ...
26 Oct 2004 ... Increased HIV survival rates generate upcoming treatment challenges · Omnitrope deferral casts doubt over biogeneric development ...
http://www.bioportfolio.co.uk/bulletin_59.htm...

Results from other life science and pharmaceutical sites:

BioSpace - BioGeneriX AG News, Search Jobs, Events
9 Nov 2006 ... BioGeneriX AG Janderstasse 3. High-Tech-Park Mannheim Mannheim D-68199 Germany Phone: 49-621-875561-0 Fax: 49-621-87556-33 ...
http://www.biospace.com/company_profile.aspx?CompanyId=70402...

XM02 is superior to placebo and equivalent to Neupogen™ in ...
This study was sponsored and funded by BioGeneriX AG. A. del Giglio has a consultancy agreement with BioGeneriX AG. H. Lubenau is an employee of
BioGeneriX ...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2628928/...

BioGeneriX AG and Neose Technologies, Inc. to Host Conference Call ...
1 Nov 2007 ... The call is expected to last approximately 30 minutes and will include prepared remarks by Neose and BioGeneriX with a subsequent question ...
http://www.biospace.com/news_story.aspx?NewsEntityId=75876...

European Union Regulatory Draft Guidance Document on Biogenerics ...
Lessons from Eprex for biogeneric firms. Nat Biotechnol. 2003 Sep; 21(9):956-7. ... Biogenerics standoff. Nat Biotechnol. 2004 Nov; 22(11):1343-6. ...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2080362/...

Neose Technologies, Inc. Announces BioGeneriX AG's Initiation Of ...
(BUSINESS WIRE)--Neose Technologies, Inc. (Nasdaq GM: NTEC) today announced that its partner, BioGeneriX AG, a company of the ratiopharm Group, ...
http://www.biospace.com/news_story.aspx?NewsEntityId=36693...

Neose Technologies, Inc. - Google Finance
The Company has an agreement with BioGeneriX AG to use the GlycoPEGylation technology to develop a long-acting version of G-CSF. Neose Technologies also
has ...
http://www.google.com/finance?q=OTC:NTEC...

BioGeneriX AG and Neose Technologies, Inc. Announce Initiation of ...
21 Mar 2007 ... (BUSINESS WIRE)--BioGeneriX AG, a member of the ratiopharm Group of companies, and Neose Technologies, Inc. (NasdaqGM:NTEC) today announced ...
http://www.biospace.com/news_story.aspx?NewsEntityId=49815...

Box 1 - Nature Biotechnology
"I agree with the EMEA and FDA on the cautious attitude they've taken towards biogenerics," says Robert Walsh, director of corporate development at ...
http://www.nature.com/nbt/journal/v21/n7/box/nbt0703-721_BX1...

1471-2407-8-332 1471-2407 Research article XM02 is superior to ...
Conflicts of interests This study was sponsored and funded by BioGeneriX AG. A. del Giglio has a consultancy agreement with BioGeneriX AG. ...
http://www.biomedcentral.com/content/download/xml/1471-2407-...

[Interchangeability of biological drugs: considerations about the ...
This indicates that the approval of a biogeneric drug requires in addition to pharmacokinetic studies, preclinical and clinical analytical studies such as ...
http://www.ncbi.nlm.nih.gov/pubmed/17277878...

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.